Organogenesis Holdings (ORGO) AI Stock Analysis

• Market Cap: $724.67M
• Dividend Yield: N/A
• Average Volume (3M): 1.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 2.24%
• EPS Growth: -67.56%
• Country: US
• Employees: 869
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.12
• Shares Outstanding: 126,912,140
• 10 Day Avg. Volume: 1,753,022
• 30 Day Avg. Volume: 1,515,726
• PEG Ratio: -5.91
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 100.90
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 1.42
• Enterprise Value/Gross Profit: 1.90
• Enterprise Value/Ebitda: 33.39
• 1Y Price Target: $9.00
• Price Target Upside: 120.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.15
• Revenue Forecast (FY): $511.05M

• Rating: 50 Neutral
• Price Target: $4.50 ▲(10.29% Upside)

Organogenesis Holdings' overall stock score reflects significant challenges in financial performance, particularly in profitability and cash flow management. Despite strong revenue growth and positive strategic developments noted in the earnings call, the negative P/E ratio and technical indicators suggest caution. The company's ability to address these financial and operational challenges will be crucial for future performance.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Organogenesis' products, enhancing market position and supporting future financial stability.

CMS Policy Favorable for Future Growth

Favorable CMS policy changes can increase product accessibility, driving long-term revenue growth and market expansion.

Positive Adjusted EBITDA

Improved EBITDA reflects better operational efficiency and profitability, enhancing the company's financial health and investment appeal.

Negative Factors

ReNu Phase III Trial Setback

The trial setback may delay product approval and commercialization, impacting future revenue streams and market competitiveness.

Cash Position Decline

A declining cash position limits financial flexibility and may hinder the company's ability to invest in growth opportunities or manage debt.

Profitability Challenges

Ongoing profitability challenges indicate inefficiencies in cost management, potentially affecting long-term financial sustainability and shareholder returns.

Organogenesis Holdings Business Overview & Revenue Model

Company Description

Organogenesis Holdings (ORGO) is a leading regenerative medicine company that specializes in developing and commercializing innovative products for the treatment of wounds and surgical procedures. The company operates primarily in the biotechnology and healthcare sectors, focusing on advanced wound care and surgical biologics. Its core products include dermal regeneration matrices, cellular therapies, and other regenerative medicine solutions designed to enhance healing and improve patient outcomes.

How the Company Makes Money

Organogenesis generates revenue through the sale of its regenerative medicine products, primarily targeting hospitals, clinics, and healthcare providers. The company has established key revenue streams through its advanced wound care products, which include Apligraf and Dermagraft, as well as its surgical biologics line. Additionally, Organogenesis benefits from partnerships with healthcare facilities and providers, which help to expand its market reach and facilitate the adoption of its products. The company also engages in ongoing research and development to innovate and introduce new products, further supporting its revenue growth.

Organogenesis Holdings Financial Statement Overview

Summary

Organogenesis Holdings faces challenges in profitability and cash flow management, despite maintaining a solid balance sheet with low leverage. The income statement shows mixed performance with slight revenue growth but negative net profit and EBIT margins. The cash flow analysis reveals significant challenges with negative operating and free cash flow, despite a positive growth rate. Overall, the company needs to improve operational efficiency and cash flow generation.

Income Statement

Organogenesis Holdings shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a slight revenue growth of 8.31%, but the company struggles with profitability, as evidenced by a negative net profit margin of -1.89% and an EBIT margin of -5.90%. The gross profit margin remains relatively healthy at 48.43%, suggesting some operational efficiency. However, the declining EBITDA margin to 0.74% highlights challenges in managing operating expenses.

Balance Sheet

The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.16, indicating conservative leverage. However, the return on equity is negative at -2.57%, pointing to inefficiencies in generating returns for shareholders. The equity ratio of 75.71% suggests a strong capital structure with significant equity backing.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating cash flow and free cash flow in the TTM period. Despite a positive free cash flow growth rate of 11.39%, the operating cash flow to net income ratio is -0.43, indicating cash flow issues relative to earnings. The free cash flow to net income ratio of 1.33 suggests reliance on non-operating sources for cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	464.99M	482.04M	433.14M	450.89M	467.36M	338.30M
Gross Profit	346.34M	366.30M	326.66M	345.87M	353.16M	250.98M
EBITDA	19.75M	15.76M	36.03M	40.32M	87.00M	37.23M
Net Income	1.00M	861.00K	4.95M	15.53M	94.20M	17.23M
Balance Sheet
Total Assets	509.83M	497.89M	460.02M	449.36M	443.26M	290.22M
Cash, Cash Equivalents and Short-Term Investments	64.37M	135.57M	104.34M	102.48M	113.93M	84.39M
Total Debt	40.81M	43.31M	119.35M	123.79M	132.30M	84.77M
Total Liabilities	123.85M	112.57M	181.36M	183.69M	201.92M	148.41M
Stockholders Equity	385.98M	385.32M	278.66M	265.67M	241.34M	141.81M
Cash Flow
Free Cash Flow	-51.65M	4.18M	6.55M	-9.04M	30.76M	-12.21M
Operating Cash Flow	-38.79M	14.21M	30.92M	24.86M	61.98M	5.47M
Investing Cash Flow	-12.86M	-10.03M	-24.36M	-33.90M	-31.22M	-23.50M
Financing Cash Flow	21.10M	27.64M	-5.50M	-2.20M	-1.04M	42.47M

Organogenesis Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Positive. The current price of 4.08 is below the 20-day moving average (MA) of 5.12, below the 50-day MA of 4.92, and below the 200-day MA of 4.43, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 64.07 is Neutral, neither overbought nor oversold. The STOCH value of 90.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORGO.

Organogenesis Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	73 Outperform	$447.57M	5.99	39.94%	―	-0.85%	-13.50%
EBS	71 Outperform	$672.78M	9.69	13.92%	―	-29.91%	―
ESPR	56 Neutral	$965.82M	-7.24	―	―	2.83%	13.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORGO	50 Neutral	$724.67M	-58.61	0.30%	―	2.24%	-67.56%
EOLS	50 Neutral	$466.05M	-7.46	―	―	15.10%	0.18%
SNDL	48 Neutral	$460.92M	-7.07	-7.82%	―	1.76%	18.31%

Organogenesis Holdings Corporate Events

Organogenesis Holdings Faces Setback in ReNu Phase 3 Trial

On September 25, 2025, Organogenesis Holdings announced that its second Phase 3 trial of ReNu, a cryopreserved amniotic suspension allograft for knee osteoarthritis, did not achieve statistical significance for its primary endpoint. Despite this, the trial showed a numerical improvement in baseline pain reduction and maintained a favorable safety profile. The company plans to request a pre-Biologics License Application meeting with the FDA to discuss using combined data from both Phase 3 studies to support a BLA approval, emphasizing ReNu’s potential to address unmet medical needs in knee osteoarthritis.